Wave Life Sciences’ Consensus Target Rises to $32 After Q4 Revenue Beat
Analysts raised Wave Life Sciences’ consensus price target from $29.79 to $32, driven by clinical progress and Pfizer and Takeda collaborations. The company posted a Q4 loss of $0.30 per share versus a $0.28 estimate but beat revenue projections.
1. Rising Consensus Price Target
Wave Life Sciences’ average consensus price target climbed from $29.79 last year to $31.88 in the prior quarter and reached $32 in the latest month, signaling growing analyst confidence in the company’s prospects.
2. Q4 Financial Results
The company reported a Q4 loss of $0.30 per share, slightly below the $0.28 estimate, but outperformed revenue projections, indicating operational resilience despite deeper year-over-year losses versus $0.17 per share in the same period last year.
3. Clinical Pipeline and Partnerships
Wave advances stereopure oligonucleotides targeting ALS, Huntington’s disease and Duchenne muscular dystrophy with its PRISM platform, while collaboration agreements with Pfizer and Takeda enhance research capacity and potential market reach.
4. Analyst Outlook and Targets
Analyst price targets vary, with some firms setting conservative $11 projections; upcoming clinical trial milestones and data releases are likely to drive future revisions to forecasts and investor sentiment.